276 related articles for article (PubMed ID: 22022270)
1. The anti-sigma factor TcdC modulates hypervirulence in an epidemic BI/NAP1/027 clinical isolate of Clostridium difficile.
Carter GP; Douce GR; Govind R; Howarth PM; Mackin KE; Spencer J; Buckley AM; Antunes A; Kotsanas D; Jenkin GA; Dupuy B; Rood JI; Lyras D
PLoS Pathog; 2011 Oct; 7(10):e1002317. PubMed ID: 22022270
[TBL] [Abstract][Full Text] [Related]
2. Human hypervirulent Clostridium difficile strains exhibit increased sporulation as well as robust toxin production.
Merrigan M; Venugopal A; Mallozzi M; Roxas B; Viswanathan VK; Johnson S; Gerding DN; Vedantam G
J Bacteriol; 2010 Oct; 192(19):4904-11. PubMed ID: 20675495
[TBL] [Abstract][Full Text] [Related]
3. Mathematical modelling reveals properties of TcdC required for it to be a negative regulator of toxin production in Clostridium difficile.
Jabbari S; Cartman ST; King JR
J Math Biol; 2015 Mar; 70(4):773-804. PubMed ID: 24687436
[TBL] [Abstract][Full Text] [Related]
4. Molecular analysis of the pathogenicity locus and polymorphism in the putative negative regulator of toxin production (TcdC) among Clostridium difficile clinical isolates.
Spigaglia P; Mastrantonio P
J Clin Microbiol; 2002 Sep; 40(9):3470-5. PubMed ID: 12202595
[TBL] [Abstract][Full Text] [Related]
5. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe.
Warny M; Pepin J; Fang A; Killgore G; Thompson A; Brazier J; Frost E; McDonald LC
Lancet; 2005 Sep 24-30; 366(9491):1079-84. PubMed ID: 16182895
[TBL] [Abstract][Full Text] [Related]
6. Toxin B is essential for virulence of Clostridium difficile.
Lyras D; O'Connor JR; Howarth PM; Sambol SP; Carter GP; Phumoonna T; Poon R; Adams V; Vedantam G; Johnson S; Gerding DN; Rood JI
Nature; 2009 Apr; 458(7242):1176-9. PubMed ID: 19252482
[TBL] [Abstract][Full Text] [Related]
7. Lack of association between clinical outcome of Clostridium difficile infections, strain type, and virulence-associated phenotypes.
Sirard S; Valiquette L; Fortier LC
J Clin Microbiol; 2011 Dec; 49(12):4040-6. PubMed ID: 21956985
[TBL] [Abstract][Full Text] [Related]
8. Analysis of TcdB Proteins within the Hypervirulent Clade 2 Reveals an Impact of RhoA Glucosylation on Clostridium difficile Proinflammatory Activities.
Quesada-Gómez C; López-Ureña D; Chumbler N; Kroh HK; Castro-Peña C; Rodríguez C; Orozco-Aguilar J; González-Camacho S; Rucavado A; Guzmán-Verri C; Lawley TD; Lacy DB; Chaves-Olarte E
Infect Immun; 2016 Jan; 84(3):856-65. PubMed ID: 26755157
[TBL] [Abstract][Full Text] [Related]
9. Precise manipulation of the Clostridium difficile chromosome reveals a lack of association between the tcdC genotype and toxin production.
Cartman ST; Kelly ML; Heeg D; Heap JT; Minton NP
Appl Environ Microbiol; 2012 Jul; 78(13):4683-90. PubMed ID: 22522680
[TBL] [Abstract][Full Text] [Related]
10. TcdC does not significantly repress toxin expression in Clostridium difficile 630ΔErm.
Bakker D; Smits WK; Kuijper EJ; Corver J
PLoS One; 2012; 7(8):e43247. PubMed ID: 22912837
[TBL] [Abstract][Full Text] [Related]
11. Clostridium difficile infection in an Iranian hospital.
Jalali M; Khorvash F; Warriner K; Weese JS
BMC Res Notes; 2012 Mar; 5():159. PubMed ID: 22436392
[TBL] [Abstract][Full Text] [Related]
12. Spo0A differentially regulates toxin production in evolutionarily diverse strains of Clostridium difficile.
Mackin KE; Carter GP; Howarth P; Rood JI; Lyras D
PLoS One; 2013; 8(11):e79666. PubMed ID: 24236153
[TBL] [Abstract][Full Text] [Related]
13. The emergence of 'hypervirulence' in Clostridium difficile.
Cartman ST; Heap JT; Kuehne SA; Cockayne A; Minton NP
Int J Med Microbiol; 2010 Aug; 300(6):387-95. PubMed ID: 20547099
[TBL] [Abstract][Full Text] [Related]
14. Epidemic ribotypes of Clostridium (now Clostridioides) difficile are likely to be more virulent than non-epidemic ribotypes in animal models.
Vitucci JC; Pulse M; Tabor-Simecka L; Simecka J
BMC Microbiol; 2020 Feb; 20(1):27. PubMed ID: 32024477
[TBL] [Abstract][Full Text] [Related]
15. Importance of toxin A, toxin B, and CDT in virulence of an epidemic Clostridium difficile strain.
Kuehne SA; Collery MM; Kelly ML; Cartman ST; Cockayne A; Minton NP
J Infect Dis; 2014 Jan; 209(1):83-6. PubMed ID: 23935202
[TBL] [Abstract][Full Text] [Related]
16. Truncation in the tcdC region of the Clostridium difficile PathLoc of clinical isolates does not predict increased biological activity of Toxin B or Toxin A.
Murray R; Boyd D; Levett PN; Mulvey MR; Alfa MJ
BMC Infect Dis; 2009 Jun; 9():103. PubMed ID: 19558711
[TBL] [Abstract][Full Text] [Related]
17. Emergence of Clostridium difficile ribotype 027 in Korea.
Kim H; Lee Y; Moon HW; Lim CS; Lee K; Chong Y
Korean J Lab Med; 2011 Jul; 31(3):191-6. PubMed ID: 21779194
[TBL] [Abstract][Full Text] [Related]
18. Prophage-stimulated toxin production in Clostridium difficile NAP1/027 lysogens.
Sekulovic O; Meessen-Pinard M; Fortier LC
J Bacteriol; 2011 Jun; 193(11):2726-34. PubMed ID: 21441508
[TBL] [Abstract][Full Text] [Related]
19. The role of flagella in Clostridium difficile pathogenicity.
Stevenson E; Minton NP; Kuehne SA
Trends Microbiol; 2015 May; 23(5):275-82. PubMed ID: 25659185
[TBL] [Abstract][Full Text] [Related]
20. Variations in virulence and molecular biology among emerging strains of Clostridium difficile.
Hunt JJ; Ballard JD
Microbiol Mol Biol Rev; 2013 Dec; 77(4):567-81. PubMed ID: 24296572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
